by Adam J. Fein, Ph.D.
(134 page downloadable PDF file; Released January 2012)
 Corporate License
$1,090(Allows for use of the report by an unlimited number of employees within the same organization or enterprise worldwide. View License Terms.) Single-User License
$380(Allows for use of the report by one individual person. View License Terms.) Payment can be made with all major credit cards (Visa, MasterCard, American Express, and Discover) or via PayPal. License terms, purchaser's name/email, and a unique transaction ID will be added to the secure PDF file upon checkout. Please contact us if you would like to upgrade from the Single-User License to a Corporate License. All sales are final after download. The pharmacy industry continues to expand and change. In 2011, Americans filled more than 4 billion prescriptions at 60,000 retail and specialty pharmacies. Total industry revenues will be nearly $275 billion. For anyone who wants to understand and benefit from the forces reshaping the highly competitive U.S. pharmacy industry, the 2011–12 Economic Report on Retail and Specialty Pharmacies is an invaluable planning tool. This all-new report was researched and written by Adam. J. Fein, Ph.D., one of the world’s leading experts on the industry and author of the influential Drug Channels blog. Dr. Fein has synthesized a wealth of financial data, research studies, and his own unique business consulting experience into a definitive, nonpartisan up-to-the-minute resource. The report includes 62 data-packed exhibits and an extensive bibliography with hyperlinks to original source materials. This year’s report—42 pages longer than the 2010-11 edition—includes expanded coverage of specialty pharmaceuticals, new market data, and more-detailed analyses of reimbursement trends. The 2011–12 Economic Report on Retail and Specialty Pharmacies is essential for pharmaceutical manufacturers, wholesalers, pharmacy owners, benefit managers, managed care executives, healthcare policy analysts, investors—anyone who wants to understand and benefit from this ever-evolving industry. The report will:
No other report on the market offers the depth, insight and analysis of the 2011-12 Economic Report on Retail and Specialty Pharmacies. Download your copy today! Please note that purchase of the 2011-12 Economic Report on Retail and Specialty Pharmacies indicates agreement with the terms and conditions of the End User License Agreement (EULA). License terms, purchaser's name/email, and a unique transaction ID will be added to the secure PDF file upon checkout. You must purchase the Corporate License if you want to share the report with other people in your company. Upon request, we will refund duplicate purchases of a Corporate License from the same organization.
|
Pembroke Consulting, Inc., grants to Purchaser, and Purchaser hereby accepts, a limited, terminable, revocable, nontransferable, nonexclusive, nonsublicenseable license to access and use the 2011-12 Economic Report on Retail and Specialty Pharmacies only in accordance with the End User License Agreement. License terms, purchaser's name/email, and a unique transaction ID will be added to the secure PDF file upon checkout. We offer two License Options:
-
Single User License: This license allows for use of this report by one individual person. This person may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any other person or persons. Unless a Corporate License is purchased, a Single User License must be purchased for every person who wishes to use the report within the same organization or enterprise. Buyers who infringe upon these license terms are liable for a Corporate License fee.
-
Corporate License: This license allows for use of the report by an unlimited number of employees within the same organization or enterprise worldwide. Each of the employees within this organization or enterprise may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any other person or persons outside the enterprise or organization.
The 2011-12 Economic Report on Retail and Specialty Pharmacies is protected by copyright law. Unauthorized reproduction or distribution of this report, or any portion of it, may result in severe civil and criminal penalties, and will be prosecuted to the maximum extent of the law.
Chapter 1: Industry Overview
-
Products Dispensed by Pharmacies
-
Industry Structure
-
Overall Market Share by Company
-
Market Share for Specialty Pharmaceuticals
-
Clinics and Other Healthcare Services
Chapter 2: Changes in Pharmacy Industry
Structure
-
Overall Growth
-
Growth by Dispensing Format
-
Recent Growth Trends
-
Independent Drugstores
-
Mail-Order Pharmacies
-
Chapter 3: Prescription Prices and Top
Drugs
-
Traditional Drugs
-
Specialty Drugs
-
Consumer Copayments and Coinsurance
Chapter 4: Relationships with Pharmacy
Benefit Managers
-
PBM Industry Overview
-
Role and Function of PBMs for Plan Sponsors
-
Retail Pharmacy Participation in PBM Networks
-
Pharmacy Networks
-
PBM-Pharmacy Relationships
-
The Efficiencies of Pharmacy Networks
-
PBM Compensation for Pharmacy Networks
-
-
Pharmacy Services Administration Organizations
Chapter 5: Pharmacy Reimbursement by
Third-Party Payers
-
The Basics of Pharmacy Reimbursement
-
-
Reimbursement for Brand-Name and Specialty Prescriptions
-
Reimbursement for Generic Prescriptions
-
Cost-Plus Methodologies
-
Average Acquisition Cost
-
Direct-to-Payer Acquisition Cost
-
Average Manufacturer Price
-
Average Sales Price
-
-
Reimbursement of Mail-Order Pharmacies
Chapter 6: Relationships with
Pharmaceutical Wholesalers
-
Wholesale Suppliers to Pharmacies
-
Purchasing Strategy of Smaller Pharmacies
-
Pharmacy Buying Groups
-
Self-Warehousing Chains and Mail-Order Pharmacies
Chapter 7: Pharmacy Profitability
-
Overall Drugstore Gross Margins
-
Gross Margins on Prescriptions
-
Gross Profits from Brand-Name Prescriptions
-
Gross Profits of Brand vs. Generic Prescriptions
-
Lifecycle Profits for Generic Drugs
-
PBM Profits from Network and Mail Pharmacies
Chapter 8: Economic Trends and Outlook
-
Pharmaceutical Market Growth
-
Summary
-
The Outlook for U.S. Pharmacy Spending
-
Projected Growth in Drug Trend
-
Payment for Prescription Drugs Under Healthcare Reform
-
-
Capturing the Specialty Opportunity
-
Summary
-
The Shift to Specialty Drugs
-
The Boom in Specialty Dispensing
-
The Medical Spend Opportunity
-
Preferred and Limited Pharmacy Networks
-
Summary
-
Pharmacy Network Models
-
Preferred Networks
-
Limited Networks
-
Limited Networks for Specialty Drugs
-
Outlook
-
-
Risk and Reward from the Generic Wave
-
Summary
-
The Generic Wave
-
Retail Pharmacy Generic Price War
-
Payer-Led Margin Compression
-
-
The Impact of New Prescription Reimbursement Benchmarks
-
Summary
-
The Benefits of Average Cost Benchmarks for Pharmacies
-
Lessons from Cost-Plus Reimbursement for Specialty Drugs
-
The Downsides of Cost-Plus Reimbursement for Pharmacies
-
Endnotes
Exhibit 1: Health Plan Criteria for Identifying a
Specialty Drug, 2011
Exhibit 2: Overview of U.S. Pharmacy Market, 2010
Exhibit 3: Average Annual Number of Prescriptions
per Pharmacy, 2010
Exhibit 4: Largest U.S. Pharmacies Ranked by Total
Prescription Revenues, 2011
Exhibit 5: Prescription Revenue Share by Chain, Top
20 U.S. Markets, 2011
Exhibit 6: Pharmacy Revenues from Specialty
Pharmaceuticals, by Company, 2010
Exhibit 7: Leading Specialty Reimbursement Hub
Providers
Exhibit 8: Channels to the Patient for Specialty
Drugs
Exhibit 9: Actual vs. Desired Work Activities for
Pharmacists Working Full-Time
Exhibit 10: U.S. Prescriptions, Annual Total and
Growth, 2000-2010
Exhibit 11: U.S. Pharmacy Revenues, Annual Total
and Growth, 2000-2010
Exhibit 12: Drugstore Revenues vs. U.S. Retail
Sales, 2000-2011:Q3
Exhibit 13: Share of Revenue Growth by Dispensing
Pharmacy Format, 2000 vs. 2010
Exhibit 14: Number of Pharmacies by Dispensing
Format (Thousands), 2000 vs. 2010
Exhibit 15: Average Prescription Revenue per
Pharmacy Outlet, 2000 vs. 2010
Exhibit 16: Median Wait Time to Fill a
Prescription, by Dispensing Format, 2010
Exhibit 17: Number of Prescriptions by Dispensing
Format, 2009 vs. 2010
Exhibit 18: Prescription Revenues by Dispensing
Format, 2009 vs. 2010
Exhibit 19: Number of Independent Pharmacies,
1990-2010
Exhibit 20: Pharmacy Franchise and Marketing
Programs of Large Drug Wholesalers
Exhibit 21: Adjusted Mail Prescriptions, Annual
Total and Growth, 2000-2010
Exhibit 22: Average Pharmacy Revenue per
Prescription, Brand vs. Generic, 1990-2010
Exhibit 23: Top 10 Brand Drugs by Retail Pharmacy
Dollars, 2010
Exhibit 24: Top 10 Generic Drugs by Retail Pharmacy
Dollars, 2010
Exhibit 25: Top Specialty Therapy Classes and
Specialty Drugs, 2010
Exhibit 26: Drug Trend, Traditional vs. Specialty
Drugs, 2010
Exhibit 27: Out-of-Pocket Spending, Retail Sales of
Prescription Drugs, 1970-2020
Exhibit 28: Average Copayments by Prescription Drug
Tier, 2000-2011
Exhibit 29: Rate of Prescription Abandonment by
Copayment
Exhibit 30: U.S. Retail Prescription Claims, by
PBM, 2012E
Exhibit 31: Medicare Part D PDP Enrollment, by
Parent Organization, 2011
Exhibit 32: Largest Pharmacy Services
Administration Organizations, 2011
Exhibit 33: Average Reimbursement for Specialty
Drugs, by Channel, 2011
Exhibit 34: Benchmark Drug Price vs. Pharmacy
Invoice Price, 2010
Exhibit 35: Brand Reimbursement Rates, Retail vs.
Mail-Order Pharmacies, 2011
Exhibit 36: Percentage of AWP Billed to Employer,
Retail vs. Mail-Order, 1999-2011
Exhibit 37: Generic Reimbursement Rates, Retail vs.
Mail-Order Pharmacies, 2011
Exhibit 38: Drug Wholesaler Sales by Type of
Customer, 2010
Exhibit 39: Drug Distribution and Related Revenues
at Big Three Wholesalers, 2011
Exhibit 40: Market Share with Smaller Pharmacies,
by Wholesaler, 2011
Exhibit 41: Pharmacy Buying Groups and Wholesaler
Relationship
Exhibit 42: Overall Gross Margins for Pharmacies
and Drugstores, 1993-2009
Exhibit 43: Overall Gross Margins for Drugstores,
2010
Exhibit 44: Average Prescription Gross Margins at
Independent Drugstores, 2006-2010
Exhibit 45: Average Prescription Gross Margins at
Independent Drugstores, By Payer, 2009
Exhibit 46: Estimated Gross Profit from a
Brand-Name Prescription, 2000-2010
Exhibit 47: Share of Pharmacy Revenues, by Channel
Participant and Drug Type, 2010
Exhibit 48: Pharmacy Profits During the 180-Day
Generic Exclusivity Period
Exhibit 49: PBM EBITDA per Equivalent Script, by
Channel and Drug Type, 2011
Exhibit 50: Growth in National Health and
Prescription Drug Expenditures, 2010-2020
Exhibit 51: U.S. Spending on Retail Prescription
Drugs and Healthcare Reform, 2009-2020
Exhibit 52: Drug Trend Forecasts, 2011-2013
Exhibit 53: Source of Payment for Retail Sales of
Prescription Drugs, 1970-2020
Exhibit 54: Fastest-Growing Private Specialty
Pharmacies, 2011
Exhibit 55: Public Payer Share of Selected
Specialty Drugs in Retail Pharmacies, 2010
Exhibit 56: Medical Benefit vs. Pharmacy Benefit
Spending on Specialty Drugs
Exhibit 57: Channels to the Patient for Specialty
Drugs with White Bagging
Exhibit 58: Infused Therapy Sourcing at Oncology
Practices, 2011
Exhibit 59: Projected Brand Revenues Lost Due to
Generic Launches, 2011-2021
Exhibit 60: Distribution of Per-Unit Weighted
Average AMPs, September 2011
Exhibit 61: Medicare Part B Spending on
Office-Administered Drugs, 1997-2009
Exhibit 62: Wholesaler and Provider Profits from a Specialty Generic Injectable Drug
